A 5-month, prospective, open-label, nonrandomized single-center study to evaluate the effects of addition of Ivabradine to β-Blocker improves exercise capacity in systolic heart failure patients
Latest Information Update: 08 Dec 2015
At a glance
- Drugs Ivabradine (Primary) ; Carvedilol
- Indications Heart failure
- Focus Therapeutic Use
Most Recent Events
- 08 Dec 2015 New trial record